Walter TJ, et al. - Researchers examined the tolerability and possible efficacy of combined naltrexone and bupropion in decreasing binge drinking in humans. In this open-label, single-arm, 12-week, prospective study, twelve men and women who exhibited a minimum of five (men) or three (women) binge drinking episodes per month over the past 3 months were administered both bupropion-extended release 300 mg/day and naltrexone 50 mg/day. The participants exhibited a reduction in the average number of drinks per binge drinking day from 7.8 drinks to 6.4 drinks and a decrease in the average percentage of binge drinking days per month from 19% (5.7 days/month) to 5% (1.5 days/month) following receipt of treatment with combined naltrexone and bupropion. Further, they showed good tolerability to the combination, with insomnia, headache and nausea/diarrhea being the most common side effects. After the trial, six individuals selected to stay on medication. Findings emphasize further investigating combined naltrexone and bupropion therapy for tolerability and efficacy in reducing binge drinking in humans.